Measuring Time to Biochemical Failure in the TROG 96.01 Trial: When Should the Clock Start Ticking?

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 4, 2009, Pages 1008-1012

  Denham, James W ^a   Steigler, Allison ^a   Kumar, Mahesh ^b   Lamb, David S ^c   Joseph, David ^d   Spry, Nigel A ^d   Tai, Keen Hun ^e   Atkinson, Chris ^f   Turner, Sandra ^g   Greer, Peter B ^h   Gleeson, Paul S ^a   D'Este, Catherine ⁱ  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c WELLINGTON HOSPITAL   (New Zealand)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

^g WESTMEAD HOSPITAL   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Androgen deprivation; Biochemical failure; Prostate cancer; Radiation therapy

Indexed keywords

ANDROGEN DEPRIVATION; BIOCHEMICAL FAILURE; COX MODEL; DATA SETS; LOCALLY ADVANCED PROSTATE CANCER; LONG-TERM ANDROGEN DEPRIVATION; OPTIMAL TIME; PROSTATE CANCERS; RADIATION ONCOLOGY; RADIATION THERAPY; TRIAL DATASET;

FLUORINE CONTAINING POLYMERS; ONCOLOGY; RADIATIVE TRANSFER;

RADIOTHERAPY;

FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTIANDROGEN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SHORT COURSE THERAPY; TREATMENT DURATION; ADJUVANT THERAPY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PALPATION; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; TIME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PALPATION; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 70449708045     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.085     Document Type: Article

References (16)

1. Denham J.W., Kumar M., Gleeson P.S., et al. Recognizing false biochemical failure calls after radiation with or without neo-adjuvent androgen deprivation for prostate cancer. Radiat Oncol Biol Phys 74 (2008) 404-411
2. Roach M.I., Hanks G., Thames H.J., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
3. Roach M.I., Lu J., Pilepich M.V., et al. Predicting long-term survival and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47 (2000) 617-627
4. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol 6 (2005) 841-850
5. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 19 (1974) 716-723
6. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
7. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
8. Denham J.W., Steigler A., D'Este C., et al. Time to biochemical failure and PSA doubling time as surrogates for prostate cancer-specific mortality. Lancet Oncol 9 (2008) 1058-1068
9. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
10. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008) 2497-2504
11. Padula G.D., Zelefsky M.J., Venkatraman E.S., et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52 (2002) 439-443
12. Murthy V., Norman A.R., Barbachano Y., et al. Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer. Br J Urol 99 (2007) 1380-1382
13. Gulley J.L., Figg W.D., Steinberg S.M., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized Phase III clinical trial using limited hormonal therapy. J Urol 173 (2005) 1567-1571
14. Pickles T., Agranovich A., Berthelet E., et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94 (2002) 362-367
15. Kaku H., Saika T., Tsushima T., et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66 (2006) 439-444
16. RADAR Trial-Randomized Androgen Deprivation and Radiotherapy. US National Institutes of Health Clinical Trials.gov, 2005. Available at: http://clinicaltrials.gov/ct/show/NCT00193856?order=5.